In 2017 we reported a case of a patient with metastatic CRC that initially tested negative for KRAS codon 12/13 mutations, and the patient’s tumors had an objective and sustained clinical and radiologic response following the addition of the EGFR inhibitor panitumumab to the same chemotherapy combination [2]. The gene discussed is KRAS; the disease is colorectal carcinoma.